To scroll text in this page

Global Navigation
Global Navigation end

About Astellas

Start of the main text

2017 News Releases

About RSS

U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia (pdf106KB)

October 11, 2017

Printer-friendly version

Main Text end
Local Navigation
Local Navigation end
Related Links